SS Innovations Appoints Milan Rao as Global COO and CFO Amid Leadership Transition

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: Jan 08 2026

0mins

SSII-5.46%

Should l Buy SSII?

Source: Globenewswire

Executive Appointment: SS Innovations announces the appointment of Milan Rao as Global Chief Operating Officer and Chief Financial Officer, succeeding Naveen Kumar Amar who resigned for personal reasons, marking a strategic leadership transition for the company.
New Role Creation: The establishment of the Global COO position aims to enhance operational efficiency and technological transformation as the company expands the global footprint of its advanced SSi Mantra surgical robotic system.
Extensive Experience: Milan Rao brings over three decades of executive leadership experience, having driven technology-enabled transformation and growth at leading global companies across various industries, which is expected to strengthen SS Innovations' financial and operational management capabilities.
Strategic Development: Rao's appointment reflects the company's commitment to attracting top talent, aiming to leverage his leadership to democratize robotic surgery and meet the needs of a broader patient population.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SSII?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SSII

About SSII

SS Innovations International, Inc. is a developer of surgical robotic technologies. The Company’s product range includes its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of surgical procedures including robotic cardiac surgery. The SSi Mantra Surgical Robotic System is designed to enable surgeons to perform a wide range of surgical procedures including cardiovascular, thoracic, head and neck, gynecological, urological, cancer and general surgeries. The SSi Mantra 3 is comprised of components, such as Surgeon Console, Patient-Side Robotic Arm Carts, and Vision Cart. Its instruments under development include NADI-Automated Coronary Anastomotic Connector, SSi Multi-Fire Clip Applier, SSi Ultrasonic Surgical Device, SSi Maya-XR Pre-Operative Simulator, SSi Holographic Anatomy, SSi Yog-Tele Proctor, SSi Chitrasa-Advanced DICOM Viewer and SSi Mixed Reality Headset.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

U.S. Stock Futures Decline, Novo Nordisk Shares Drop

Feb 23 2026Benzinga

Futures Decline: U.S. stock futures are lower this morning, with Dow futures falling approximately 100 points, indicating a cautious market sentiment that may lead investors to adopt more conservative strategies in the short term.
Novo Nordisk Stock Drop: Novo Nordisk shares fell 8% to $43.60 in pre-market trading, reflecting market concerns about the company's future performance, which could impact investor confidence in the pharmaceutical sector.
Market Sentiment Weakens: The overall market sentiment is influenced by multiple factors, including uncertainties in economic data and investor concerns regarding future interest rate policies, potentially leading to downward pressure on more stocks in the near term.
Investor Strategy Adjustment: As stock futures decline, investors may reassess their portfolios and shift towards more stable asset allocations to mitigate potential market volatility.

Vanda Pharmaceuticals Shares Surge 33% in Pre-Market Trading

Feb 23 2026Benzinga

Significant Price Surge: Vanda Pharmaceuticals' shares jumped 33% in pre-market trading to $7.65, indicating strong market confidence in its future performance, which may attract more investor interest.
Positive Market Reaction: This price surge reflects optimistic expectations from investors regarding Vanda's potential growth opportunities, potentially facilitating further development in the biopharmaceutical sector.
Increased Trading Activity: With the notable price increase, Vanda's trading volume is likely to rise, providing the company with enhanced liquidity to support its R&D and market expansion plans.
Improved Investor Sentiment: The rise in Vanda's stock price may enhance overall investor sentiment, particularly in the biopharmaceutical industry, further boosting the performance of related stocks.

HubSpot Reports Strong Q3 Earnings, Shares Surge 9.4%

Feb 12 2026Benzinga

Earnings Beat: HubSpot reported quarterly earnings of $3.09 per share, surpassing analyst expectations of $2.99, indicating robust profitability and boosting market confidence in the company's future performance.
Significant Revenue Growth: The quarterly revenue reached $846.75 million, exceeding the Street estimate of $830.54 million and marking a 20.4% increase from $703.17 million in the same period last year, showcasing HubSpot's competitive strength in the market.
Stock Price Surge: Following the positive earnings report, HubSpot's shares jumped 9.4% to $228.93 on Thursday, reflecting investor optimism about the company's growth potential and likely attracting more investor interest.
Mixed Market Performance: While U.S. stocks showed mixed results overall, HubSpot's strong performance distinguished it among many stocks, demonstrating relative resilience and appeal in a fluctuating market.

SS Innovations Reports Q4 2025 Revenue of $15M, Up 85% Year-over-Year

Jan 13 2026NASDAQ.COM

Significant Revenue Growth: SS Innovations anticipates Q4 2025 revenue of approximately $15 million, representing an 85% increase from $8.1 million in Q4 2024, showcasing strong performance in the global market.
Increased System Installations: By the end of Q4 2025, the number of SSi Mantra surgical robot installations rose to 37, up from 22 in the same quarter last year, reflecting a sustained demand for its products.
Impressive Annual Performance: Full-year 2025 revenue is projected to reach $43 million, a 108% increase from $20.6 million in 2024, with annual installations totaling 103, significantly up from 47 in 2024, bringing the cumulative installed base to 168 systems.
Positive Future Outlook: The company expects to complete the FDA 510(k) review for the SSi Mantra system in the first half of 2026, while also advancing towards EU CE Mark certification in the same timeframe, further solidifying its market position.

SS Innovations (SSII) Expects 2025 Revenue of $43 Million, Up 108%

Jan 13 2026Globenewswire

Significant Revenue Growth: SS Innovations anticipates fourth-quarter 2025 revenue of approximately $15 million, an 85% increase from $8.1 million in the fourth quarter of 2024, indicating strong performance driven by rising market demand.
Installation Numbers Surge: The company expects to report 37 SSi Mantra installations in Q4 2025, up 68% from 22 installations in Q4 2024, reflecting increasing acceptance and demand for its products in the global market.
Annual Performance Breakthrough: For the full year 2025, SS Innovations projects revenue of approximately $43 million, an increase of 108% from $20.6 million in 2024, showcasing a significant enhancement in market share and sales capabilities in the surgical robotics sector.
Market Expansion Plans: The company aims to complete FDA review and EU CE certification for the SSi Mantra in the first half of 2026, further driving its expansion in the U.S. and European markets and enhancing its global competitiveness.